Spectacle Independence and Overall Satisfaction With AcrySof® Panoptix® Toric Intraocular Lens

Sponsor
Eye Center of North Florida (Other)
Overall Status
Terminated
CT.gov ID
NCT04128514
Collaborator
Science in Vision (Other)
15
1
28.9
0.5

Study Details

Study Description

Brief Summary

The study was designed to assess the spectacle independence and satisfaction of patients receiving the AcrySof® Panoptix® Toric intraocular lens (IOL) after uneventful cataract surgery.

Condition or Disease Intervention/Treatment Phase
  • Device: Panoptix Toric

Detailed Description

This study is a single-arm unmasked clinical evaluation study of spectacle independence after successful bilateral cataract surgery. Subjects will be assessed pre-operatively, operatively and at 1 day, 1 month and 3 months post-operatively. Clinical evaluations will include administration of a spectacle independence and a quality of life questionnaire, as well as measurement of bilateral visual acuity and manifest refraction.

Study Design

Study Type:
Observational
Actual Enrollment :
15 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Spectacle Independence and Overall Satisfaction With Bilateral Implantation of the AcrySof® Panoptix® Toric Intraocular Lens
Actual Study Start Date :
Oct 11, 2019
Actual Primary Completion Date :
Mar 10, 2022
Actual Study Completion Date :
Mar 10, 2022

Arms and Interventions

Arm Intervention/Treatment
Enrolled subjects

Subjects ≥40 years of age presenting for cataract surgery who are interested in reducing their dependence on spectacles at all distances, and who are appropriate candidates for multifocal lens implantation. The Acrysof (R) Panoptix (R) Toric intraocular lens will be implanted in both eyes of subjects.

Device: Panoptix Toric
Cataract surgery and IOL implantation

Outcome Measures

Primary Outcome Measures

  1. Spectacle independence - emmetropia [3 months]

    Percent of patients with ≤ 0.5D of refractive cylinder and ≤ 0.50D of absolute residual spherical equivalent refraction postoperatively who never or rarely wear spectacles for distance, intermediate or near vision 3 months postop (based on the Patient-Reported Spectacle Independence Questionnaire, or PRSIQ1 - "a little of the time" or "none of the time")

Secondary Outcome Measures

  1. Binocular uncorrected distance visual acuity [3 months]

    Binocular distance visual acuity

  2. Binocular uncorrected intermediate visual acuity [3 months]

    Binocular intermediate visual acuity

  3. BInocular uncorrected near visual acuity [3 months]

    Binocular near visual acuity

  4. Binocular best-corrected distance visual acuity [3 months]

    Binocular best-corrected distance visual acuity

  5. Binocular distance-corrected intermediate visual acuity [3 months]

    Binocular distance-corrected intermediate visual acuity

  6. Binocular distance-corrected near visual acuity [3 months]

    Binocular distance-corrected near visual acuity

  7. Spherical equivalent refraction [3 months]

    Spherical equivalent refraction

  8. Residual astigmatism [3 months]

    Residual astigmatism

  9. Uncorrected preferred reading distance [3 months]

    Uncorrected preferred reading distance

  10. Monocular corrected distance visual acuity [3 months]

    Monocular corrected distance visual acuity

  11. Spectacle independence - overall [3 months]

    Percent of all patients who never or rarely wear spectacles for distance, intermediate or near vision 3 months postop (based on the Patient-Reported Spectacle Independence Questionnaire, or PRSIQ1 - "a little of the time" or "none of the time")

  12. Binocular uncorrected visual acuity at preferred reading distance [3 months]

    Binocular uncorrected visual acuity at preferred reading distance

  13. VFQ-14 [3 months]

    Questionnaire responses on VFQ-14 visual function questionnaire

  14. Choose lens again [3 months]

    Percent of patients who would choose this lens modality again.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Inclusion Criteria

Subjects are eligible for the study if they meet the following criteria:

Note: Ocular criteria must be met in both eyes.

  • Presenting for uncomplicated bilateral cataract surgery and have an interest in spectacle independence using a multifocal toric IOL option

  • Gender: Males and Females.

  • Age: 40 or older.

  • Willing and able to provide written informed consent for participation in the study.

  • Willing and able to comply with scheduled visits and other study procedures.

  • Have good ocular health, with no pathology that compromises visual acuity (outside of residual refractive error and cataract)

  • Have regular corneal astigmatism with a magnitude that can be treated with a toric IOL in the approved range (T3-T6) for the Panoptix lens.

  • Have 20/32 (0.2 logMAR) or better potential acuity in both eyes

Exclusion Criteria If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

  • Irregular astigmatism (e.g. keratoconus)

  • Corneal pathology (e.g. scar, dystrophy, pterygium, moderate-to-severe dry eye)

  • Monocular status (e.g. amblyopia)

  • Previous radial keratotomy, corneal refractive surgery or other corneal surgery (e.g. corneal transplant, DSAEK, lamellar keratoplasty)

  • Previous anterior or posterior chamber surgery (e.g., vitrectomy, laser iridotomy)

  • Diabetic retinopathy

  • Macular pathology (e.g. ARMD, ERM)

  • History of retinal detachment

  • Subjects who have an acute or chronic disease or illness that would confound the results of this investigation (e.g., immunocompromised, connective tissue disease, clinically significant atopic disease, diabetes, and any other such disease or illness), that are known to affect postoperative visual acuity.

  • Participation in any investigational drug or device trial within the previous 30 days prior to the start date of this trial (or currently participating).

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eye Center of North Florida Panama City Florida United States 32409

Sponsors and Collaborators

  • Eye Center of North Florida
  • Science in Vision

Investigators

  • Principal Investigator: Bret Fisher, MD, Eye Center of North Florida

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Eye Center of North Florida
ClinicalTrials.gov Identifier:
NCT04128514
Other Study ID Numbers:
  • BF-19-001
First Posted:
Oct 16, 2019
Last Update Posted:
Apr 1, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Eye Center of North Florida
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 1, 2022